Current Environment: Production

Medical Services

Programs & Services

Languages

  • English

Education

Undergraduate School

University of Virginia

2000, Charlottesville, VA

Medical School

Vanderbilt University School of Medicine

2004, Nashville, TN

Internship

Brigham and Women's Hospital

2005, Boston, MA

Residency

Harvard Dermatology Program

2008, Boston, MA

Fellowship

Beth Israel Deaconess Medical Center

2009, Boston, MA

Certifications

  • American Board of Dermatology (General)

Publications

  1. Efficacy, safety, and target engagement of dazukibart, an IFNß specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2025 Jan 11; 405(10473):137-146. View Abstract

  2. 3-dimensional stereophotogrammetry: an effective tool for detecting disease progression in lupus erythematosus panniculitis. Clin Exp Dermatol. 2024 Nov 20. View Abstract

  3. Recent Advances in Juvenile Dermatomyositis: Moving toward Integration of Myositis-Specific Antibody Clinical Phenotypes, IFN-Driven Pathogenesis, and Targeted Therapies. J Invest Dermatol. 2024 Nov 11. View Abstract

  4. Fracture risk in linear morphea-affected limbs: A pilot retrospective study of adult patients. JAAD Int. 2025 Feb; 18:27-29. View Abstract

  5. Innovation in Dermatomyositis. Dermatol Clin. 2025 Jan; 43(1):103-110. View Abstract

  6. Area Deprivation and Disease Severity in Adult Patients With Discoid Lupus Erythematosus. JAMA Dermatol. 2024 Sep 01; 160(9):984-988. View Abstract

  7. De novo autoimmune connective tissue disease and mortality in patients treated with anti-programmed death receptor-1 and anti-programmed death-ligand 1 therapy: a population-level cohort study. Br J Dermatol. 2024 Aug 14; 191(3):460-462. View Abstract

  8. From traditional to targeted: the changing trajectory of therapies in dermatomyositis. Curr Opin Rheumatol. 2024 Nov 01; 36(6):438-444. View Abstract

  9. Anifrolumab in recalcitrant cutaneous dermatomyositis: A multicenter retrospective cohort study. J Am Acad Dermatol. 2024 Dec; 91(6):1217-1219. View Abstract

  10. Comparison of 3D facial photographs and clinical documentation in patients with craniofacial morphea. Skin Health Dis. 2024 Dec; 4(6):e438. View Abstract

  11. Publisher Correction: Interferon subverts an AHR-JUN axis to promote CXCL13+ T cells in lupus. Nature. 2024 Aug; 632(8025):E6. View Abstract

  12. Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis. Clin Exp Rheumatol. 2024 Jul 15. View Abstract

  13. Interferon subverts an AHR-JUN axis to promote CXCL13+ T cells in lupus. Nature. 2024 Jul; 631(8022):857-866. View Abstract

  14. Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative. Nat Rev Rheumatol. 2024 May; 20(5):315. View Abstract

  15. Discoid lupus erythematosus successfully treated with deucravacitinib. JAAD Case Rep. 2024 Jul; 49:59-61. View Abstract

  16. Executive summary: Consensus treatment guidelines for the use of methotrexate for inflammatory skin disease in pediatric patients. J Am Acad Dermatol. 2024 Jun; 90(6):1271-1275. View Abstract

  17. Rapid Improvement in Recalcitrant Cutaneous Juvenile Dermatomyositis With Anifrolumab Treatment. JAMA Dermatol. 2024 Feb 01; 160(2):237-238. View Abstract

  18. Depression in patients with Raynaud's phenomenon: A case-control study in the National Institutes of Health's All of Us Research Program. J Am Acad Dermatol. 2024 Apr; 90(4):857-859. View Abstract

  19. Hyaluronidase Injections for Oral Microstomia in Systemic Sclerosis and Mixed Connective Tissue Disease. JAMA Dermatol. 2023 12 01; 159(12):1393-1395. View Abstract

  20. Successful Treatment of Keloids and Hypertrophic Scars With Systemic and Intralesional Dupilumab. J Drugs Dermatol. 2023 Dec 01; 22(12):1220-1222. View Abstract

  21. International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative. Nat Rev Rheumatol. 2023 Dec; 19(12):805-817. View Abstract

  22. Use of 3-Dimensional Stereophotogrammetry to Detect Disease Progression in Craniofacial Morphea. JAMA Dermatol. 2023 11 01; 159(11):1232-1239. View Abstract

  23. Increased risk of depression in patients with discoid lupus erythematosus: a nested, case-control study in the All of Us Research Program. Br J Dermatol. 2023 10 25; 189(5):628-629. View Abstract

  24. Anifrolumab for Adolescent Discoid Lupus Erythematosus. JAMA Netw Open. 2023 10 02; 6(10):e2338200. View Abstract

  25. Improvement in mucosal discoid lupus erythematosus with anifrolumab. Clin Exp Dermatol. 2023 09 19; 48(10):1165-1167. View Abstract

  26. Utility of magnetic resonance imaging in the diagnosis of eosinophilic fasciitis: A multicenter retrospective cohort study. J Am Acad Dermatol. 2023 12; 89(6):1313-1315. View Abstract

  27. Diffuse Cutaneous Eruption. JAMA. 2023 06 27; 329(24):2187-2188. View Abstract

  28. Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines. Pediatr Dermatol. 2023 Sep-Oct; 40(5):789-808. View Abstract

  29. Intravenous Immunoglobulin and Dermatomyositis-Associated Venous Thromboembolism. JAMA Dermatol. 2023 06 01; 159(6):666-667. View Abstract

  30. Mepolizumab for refractory eosinophilic fasciitis: a retrospective analysis from two tertiary care centres. Clin Exp Rheumatol. 2023 08; 41(8):1721-1722. View Abstract

  31. Clinical features in adults with acquired cutis laxa: a retrospective review. Br J Dermatol. 2023 05 24; 188(6):800-816. View Abstract

  32. Distinctive cutaneous features of dermatomyositis in Black adults: A case series. JAAD Case Rep. 2023 Jul; 37:106-109. View Abstract

  33. Eosinophilic Fasciitis. N Engl J Med. 2023 May 11; 388(19):e65. View Abstract

  34. Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus. JAMA Dermatol. 2023 05 01; 159(5):560-563. View Abstract

  35. Botulinum toxin for refractory Raynaud's phenomenon: A "how to" guide for pediatric patients. Pediatr Dermatol. 2023 May-Jun; 40(3):587-589. View Abstract

  36. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med. 2023 01 05; 388(1):94. View Abstract

  37. Tocilizumab for refractory morphea in adults: A case series. JAAD Case Rep. 2022 Dec; 30:27-29. View Abstract

  38. Pilot use of 3-dimensional photography to aid clinical decision-making in craniofacial morphea. JAAD Case Rep. 2022 Jul; 25:100-103. View Abstract

  39. Increasing skin of color representation in a medical school dermatology course through student and faculty engagement: The Dermatology IDD Image Verification Ensuring Representation of Skin of Color initiative. J Am Acad Dermatol. 2023 02; 88(2):437-440. View Abstract

  40. Immunologic underpinnings and treatment of morphea. Expert Rev Clin Immunol. 2022 05; 18(5):461-483. View Abstract

  41. Genetic diagnosis of immune dysregulation can lead to targeted therapy for interstitial lung disease: A case series and single center approach. Pediatr Pulmonol. 2022 07; 57(7):1577-1587. View Abstract

  42. Cross-sectional characteristics of pediatric-onset discoid lupus erythematosus: Results of a multicenter, retrospective cohort study. J Am Acad Dermatol. 2022 09; 87(3):559-566. View Abstract

  43. Evaluating patient experience and satisfaction with teledermatology for isotretinoin management: a structured qualitative interview study. J Dermatolog Treat. 2022 08; 33(5):2698-2701. View Abstract

  44. Dental Anomalies in Parry-Romberg Syndrome: A 40-Year Retrospective Review. Cleft Palate Craniofac J. 2023 08; 60(8):956-961. View Abstract

  45. Treatment With Mycophenolate Mofetil for Salt-and-Pepper Dyspigmentation Caused by Autoimmune Sclerosing Disease. JAMA Dermatol. 2022 03 01; 158(3):327-329. View Abstract

  46. Crowdsourcing as a means of fundraising for juvenile dermatomyositis. Pediatr Dermatol. 2022 May; 39(3):379-381. View Abstract

  47. Characteristics and Outcomes of Eosinophilic Fasciitis-Associated Monoclonal Gammopathy. JAMA Dermatol. 2021 12 01; 157(12):1508-1509. View Abstract

  48. Corrigendum to: A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. Rheumatology (Oxford). 2021 Nov 03; 60(11):5483. View Abstract

  49. OnabotulinumtoxinA for Systemic Sclerosis-associated Raynaud's Phenomenon: A Multi-Institutional Study on Accessibility and Effectiveness. J Drugs Dermatol. 2021 Nov 01; 20(11):1257-1259. View Abstract

  50. Race and gender differences in systemic sclerosis: a retrospective multicenter cohort. Int J Dermatol. 2022 11; 61(11):e437-e438. View Abstract

  51. Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centers. J Am Acad Dermatol. 2022 02; 86(2):423-425. View Abstract

  52. Recognition and Management of Cutaneous Connective Tissue Diseases. Med Clin North Am. 2021 Jul; 105(4):757-782. View Abstract

  53. Use of Tofacitinib, 2%, Ointment for Periorbital Discoid Lupus Erythematosus. JAMA Dermatol. 2021 07 01; 157(7):880-882. View Abstract

  54. A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. Rheumatology (Oxford). 2021 06 18; 60(6):2615-2628. View Abstract

  55. Familial chilblain lupus in a child with heterozygous mutation in SAMHD1 and normal interferon signature. Br J Dermatol. 2021 09; 185(3):650-652. View Abstract

  56. Dermatology education in internal medicine residency programs: A nationwide survey of program directors. J Am Acad Dermatol. 2021 Aug; 85(2):482-484. View Abstract

  57. Treatment of Severe Multicentric Reticulohistiocytosis With Upadacitinib. JAMA Dermatol. 2021 06 01; 157(6):735-737. View Abstract

  58. Lack of association between tumor necrosis factor-a inhibitor use and exacerbation of lupus erythematosus: A retrospective cohort study. J Am Acad Dermatol. 2022 05; 86(5):1180-1182. View Abstract

  59. Increased risk of systemic and cardiac sarcoidosis in Black patients with cutaneous sarcoidosis. J Am Acad Dermatol. 2022 05; 86(5):1178-1180. View Abstract

  60. Characteristics and treatment of silicone granulomas: A retrospective multicenter cohort of 21 patients. JAAD Int. 2021 Jun; 3:111-114. View Abstract

  61. The catch-22 of limited Food and Drug Administration approval for connective tissue disease therapies. J Am Acad Dermatol. 2021 Aug; 85(2):517-519. View Abstract

  62. Clinical features and eosinophilia in pityriasis rubra pilaris: A multicenter cohort. J Am Acad Dermatol. 2022 04; 86(4):907-909. View Abstract

  63. Geographic distribution and environmental triggers of systemic sclerosis cases from 2 large academic tertiary centers in Massachusetts. J Am Acad Dermatol. 2022 04; 86(4):925-927. View Abstract

  64. Challenges of securing insurance approval for oral tofacitinib for the treatment of alopecia areata: a multi-institution retrospective review. Arch Dermatol Res. 2022 Jul; 314(5):487-489. View Abstract

  65. Porphyria Cutanea Tarda Masquerading as Systemic Sclerosis: Two Cases Demonstrating an Important Clinical Observation. J Rheumatol. 2021 01 01; 48(1):145-146. View Abstract

  66. Early Features of Progressive Hemifacial Atrophy-Clinical and Imaging Findings. JAMA Dermatol. 2020 12 01; 156(12):1376-1379. View Abstract

  67. Clinical Characteristics of Lupus Erythematosus Panniculitis/Profundus: A Retrospective Review of 61 Patients. JAMA Dermatol. 2020 11 01; 156(11):1264-1266. View Abstract

  68. Practice gaps in the evaluation of systemic involvement in patients with cutaneous sarcoidosis presenting to a dermatologist: A retrospective review of 48 patients. J Am Acad Dermatol. 2021 09; 85(3):794-796. View Abstract

  69. Strategies for effective medical student education in dermatology during the COVID-19 pandemic. J Am Acad Dermatol. 2021 01; 84(1):e33-e34. View Abstract

  70. Dermatomyositis: An Update on Diagnosis and Treatment. Am J Clin Dermatol. 2020 Jun; 21(3):339-353. View Abstract

  71. Mycophenolate Mofetil for Eosinophilic Fasciitis: A Retrospective Analysis From 3 Tertiary Care Centers. JAMA Dermatol. 2020 05 01; 156(5):595-597. View Abstract

  72. Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea. JAMA Dermatol. 2020 05 01; 156(5):521-528. View Abstract

  73. A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents. JAMA Dermatol. 2020 04 01; 156(4):384-392. View Abstract

  74. A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria. JAMA Dermatol. 2020 03 01; 156(3):270-279. View Abstract

  75. Capecitabine-Related Eruption Mimicking Dermatomyositis in 2 Patients With Metastatic Breast Cancer. JAMA Dermatol. 2020 01 01; 156(1):103-104. View Abstract

  76. Intravenous immunoglobulin for refractory eosinophilic fasciitis: A retrospective analysis from 3 tertiary care centers. J Am Acad Dermatol. 2023 06; 88(6):1354-1356. View Abstract

  77. Facing Uncertainty. N Engl J Med. 2019 Dec 05; 381(23):2253-2259. View Abstract

  78. Facing Uncertainty. N Engl J Med. 2019 Nov 28; 381(22):e39. View Abstract

  79. Willingness-to-pay stated preferences in cutaneous lupus erythematosus: a pilot study. Arch Dermatol Res. 2020 Sep; 312(7):527-531. View Abstract

  80. Cutaneous Ulcerations in Anti-MDA5 Dermatomyositis. N Engl J Med. 2019 Aug 01; 381(5):465. View Abstract

  81. Augmented reality in dermatology: Are we ready for AR? J Am Acad Dermatol. 2019 Nov; 81(5):1216-1222. View Abstract

  82. Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers. JAMA Dermatol. 2019 Apr 01; 155(4):494-496. View Abstract

  83. Clinical Features and Comorbidities of Patients With Necrobiosis Lipoidica With or Without Diabetes. JAMA Dermatol. 2019 04 01; 155(4):455-459. View Abstract

  84. Assessment of Antimalarial Therapy in Patients Who Are Hypersensitive to Hydroxychloroquine. JAMA Dermatol. 2019 Apr 01; 155(4):491-493. View Abstract

  85. Pityriasis rubra pilaris: A study evaluating patient quality of life in 2 populations. J Am Acad Dermatol. 2019 08; 81(2):638-640. View Abstract

  86. Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations. J Invest Dermatol. 2019 02; 139(2):270-276. View Abstract

  87. Academic dermatology leadership in the United States -- Addressing the gender gap. Int J Womens Dermatol. 2018 Dec; 4(4):236-237. View Abstract

  88. Dermatology subspecialty clinic for patients with connective tissue disease impacts diagnosis and treatment: A single-center, retrospective analysis. J Am Acad Dermatol. 2021 08; 85(2):476-478. View Abstract

  89. Lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease-associated calcinosis cutis. Br J Dermatol. 2018 06; 178(6):1412-1415. View Abstract

  90. Subacute Cutaneous Lupus Erythematosus Induced by Palbociclib. J Cutan Med Surg. 2018 May/Jun; 22(3):341-343. View Abstract

  91. Hidradenitis suppurativa burden of disease tool: Pilot testing of a disease-specific quality of life questionnaire. J Am Acad Dermatol. 2018 01; 78(1):215-217.e2. View Abstract

  92. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2018 04; 78(4):776-785. View Abstract

  93. Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment. Curr Rheumatol Rep. 2017 Nov 04; 19(12):74. View Abstract

  94. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis. JAMA Dermatol. 2017 11 01; 153(11):1147-1157. View Abstract

  95. Sex and leadership in academic dermatology: A nationwide survey. J Am Acad Dermatol. 2017 10; 77(4):782-784. View Abstract

  96. Characteristics and Alternative Treatment Outcomes of Antimalarial-Refractory Cutaneous Lupus Erythematosus. JAMA Dermatol. 2017 09 01; 153(9):937-939. View Abstract

  97. Antimelanoma Differentiation-associated Gene 5 Dermatomyositis. J Rheumatol. 2017 06; 44(6):850-851. View Abstract

  98. Asymptomatic papules after breast cancer treatment. J Am Acad Dermatol. 2017 May; 76(5):e157-e158. View Abstract

  99. Asymptomatic papules after breast cancer treatment. J Am Acad Dermatol. 2017 May; 76(5):e157-e158. View Abstract

  100. Novel Application of High-Dose-Rate Brachytherapy for Severe, Recalcitrant Acrodermatitis Continua of Hallopeau. JAMA Dermatol. 2017 04 01; 153(4):331-332. View Abstract

  101. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon ß in dermatomyositis. Br J Dermatol. 2017 May; 176(5):1224-1230. View Abstract

  102. Expanding the use of the Cutaneous Dermatomyositis Area and Severity Index (CDASI) to nondermatologists. Br J Dermatol. 2017 02; 176(2):296-297. View Abstract

  103. Segmental stiff skin syndrome (SSS): Two additional cases with a positive response to mycophenolate mofetil and physical therapy. J Am Acad Dermatol. 2016 Dec; 75(6):e237-e239. View Abstract

  104. Characteristics and treatment of postirradiation morphea: A retrospective multicenter analysis. J Am Acad Dermatol. 2017 Jan; 76(1):19-21. View Abstract

  105. Unilateral Gottron Papules in a Patient Following a Stroke: Clinical Insights Into the Disease Mechanisms and Pathophysiology of Cutaneous Dermatomyositis. JAMA Dermatol. 2016 09 01; 152(9):1062-3. View Abstract

  106. Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment. JAMA Dermatol. 2016 08 01; 152(8):944-5. View Abstract

  107. Thalidomide and lenalidomide for the treatment of refractory dermatologic conditions. J Am Acad Dermatol. 2016 Jul; 75(1):210-2. View Abstract

  108. Sharps injuries among US dermatology trainees: A cross-sectional study. J Am Acad Dermatol. 2016 Apr; 74(4):756-8. View Abstract

  109. Characteristics and treatment of adult-onset linear morphea: A retrospective cohort study of 61 patients at 3 tertiary care centers. J Am Acad Dermatol. 2016 Mar; 74(3):577-9. View Abstract

  110. Dapsone for treatment of erythema nodosum. Dermatol Online J. 2016 Feb 17; 22(2). View Abstract

  111. Novel application of high-dose rate brachytherapy for severe, recalcitrant palmoplantar pustulosis. Clin Exp Dermatol. 2016 Jul; 41(5):498-501. View Abstract

  112. Development and Pilot Testing of the Cutaneous Lupus Screening Tool. JAMA Dermatol. 2016 Jan; 152(1):60-6. View Abstract

  113. Epidemiology and Treatment of Eosinophilic Fasciitis: An Analysis of 63 Patients From 3 Tertiary Care Centers. JAMA Dermatol. 2016 Jan; 152(1):97-9. View Abstract

  114. Palliative Therapy for Recalcitrant Cutaneous T-Cell Lymphoma of the Hands and Feet With Low-Dose, High Dose-Rate Brachytherapy. JAMA Dermatol. 2015 Dec 01; 151(12):1354-1357. View Abstract

  115. Cutaneous dermatomyositis in the era of biologicals. Semin Immunopathol. 2016 Jan; 38(1):113-21. View Abstract

  116. Epidemiology of concomitant psoriasis and hidradenitis suppurativa (HS): experience of a tertiary medical center. J Am Acad Dermatol. 2015 Oct; 73(4):701-2. View Abstract

  117. The Value of the Black Box Warning in Dermatology. J Drugs Dermatol. 2015 Jul; 14(7):660-6. View Abstract

  118. Severe Tacrolimus-Induced Granulomatous Rosacea Recalcitrant to Oral Tetracyclines. J Drugs Dermatol. 2015 Jun; 14(6):628-30. View Abstract

  119. Teledermatology perception differences between urban primary care physicians and dermatologists. JAMA Dermatol. 2015 Mar; 151(3):339-40. View Abstract

  120. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol. 2015 Feb; 151(2):195-9. View Abstract

  121. Tense bullae on the palms and soles. JAMA Dermatol. 2015 Jan; 151(1):99-100. View Abstract

  122. Facial erythromelalgia: a rare entity to consider in the differential diagnosis of connective tissue diseases. J Am Acad Dermatol. 2014 Dec; 71(6):e250-1. View Abstract

  123. Clinicopathologic lessons in distinguishing cicatricial alopecia: 7 cases of lichen planopilaris misdiagnosed as discoid lupus. J Am Acad Dermatol. 2014 Oct; 71(4):e135-8. View Abstract

  124. Paraproteinemia-associated scleredema treated successfully with intravenous immunoglobulin. JAMA Dermatol. 2014 Jul; 150(7):788-9. View Abstract

  125. A 52-year-old woman with subcutaneous nodules and abdominal pain. Clin Exp Dermatol. 2014 Jun; 39(4):547-9. View Abstract

  126. Cumulative ultraviolet radiation flux in adulthood and risk of incident skin cancers in women. Br J Cancer. 2014 Apr 02; 110(7):1855-61. View Abstract

  127. Creation of a novel, interdisciplinary, multisite clerkship: "understanding lupus". Acad Med. 2014 Mar; 89(3):404-9. View Abstract

  128. Cutaneous lupus erythematosus. JAMA Dermatol. 2014 Mar; 150(3):344. View Abstract

  129. Treatment options for pityriasis rubra pilaris including biologic agents: a retrospective analysis from an academic medical center. JAMA Dermatol. 2014 Jan; 150(1):92-4. View Abstract

  130. Case records of the Massachusetts General Hospital. Case 39-2013. A 57-year-old woman with painful bullous skin lesions. N Engl J Med. 2013 Dec 19; 369(25):2438-49. View Abstract

  131. Multiple tense bullae localized to the right breast in a woman in her seventies. JAMA Dermatol. 2013 Dec; 149(12):1427-8. View Abstract

  132. Lupus erythematosus panniculitis-induced facial atrophy: effective treatment with poly-L-lactic acid and hyaluronic acid dermal fillers. J Am Acad Dermatol. 2013 Nov; 69(5):e260-e262. View Abstract

  133. Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity. Int J Dermatol. 2013 Nov; 52(11):1407-9. View Abstract

  134. Psoriasiform reactions to anti-tumor necrosis factor a therapy. J Clin Rheumatol. 2013 Oct; 19(7):377-81. View Abstract

  135. Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center. J Am Acad Dermatol. 2013 Oct; 69(4):654-7. View Abstract

  136. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis. JAMA Dermatol. 2013 Oct; 149(10):1204-8. View Abstract

  137. Cutaneous dermatomyositis: an updated review of treatment options and internal associations. Am J Clin Dermatol. 2013 Aug; 14(4):291-313. View Abstract

  138. Methotrexate for the treatment of cutaneous dermatomyositis. J Am Acad Dermatol. 2013 Jun; 68(6):1043-5. View Abstract

  139. Images in clinical medicine. Epidermolysis bullosa acquisita. N Engl J Med. 2013 Mar 28; 368(13):e17. View Abstract

  140. Diffuse dystrophic calcinosis cutis of the scalp in a patient with scalp discoid lupus erythematosus and systemic lupus erythematosus. JAMA Dermatol. 2013 Feb; 149(2):246-8. View Abstract

  141. Full facial edema: a novel presentation of subcutaneous panniculitis-like T-cell lymphoma. J Clin Oncol. 2012 Sep 01; 30(25):e233-6. View Abstract

  142. Calcinosis cutis: an additional therapy to consider. J Am Acad Dermatol. 2012 Jun; 66(6):1004-5; author reply 1005. View Abstract

  143. Panniculitis associated with dermatomyositis and recurrent ovarian cancer. Arch Dermatol. 2012 Jun; 148(6):740-4. View Abstract

  144. Metastatic basal cell carcinoma of the posterior neck: case report and review of the literature. J Cutan Pathol. 2012 May; 39(5):526-34. View Abstract

  145. Management of cutaneous dermatomyositis. Dermatol Ther. 2012 Mar-Apr; 25(2):112-34. View Abstract

  146. A population-based study of acne and body mass index in adolescents. Arch Dermatol. 2012 Jan; 148(1):131-2. View Abstract

  147. Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermatol. 2012 Dec; 67(6):e253-60. View Abstract

  148. Identifying when therapy for one skin disease is likely to exacerbate another skin condition. Arch Dermatol. 2011 Jul; 147(7):836. View Abstract

  149. Psoriatic alopecia/alopecia areata-like reactions secondary to anti-tumor necrosis factor-a therapy: a novel cause of noncicatricial alopecia. Am J Dermatopathol. 2011 Apr; 33(2):161-6. View Abstract

  150. RNA interference of insulin-related peptide and neuroparsins affects vitellogenesis in the desert locust Schistocerca gregaria. Peptides. 2011 Mar; 32(3):573-80. View Abstract

  151. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-a inhibitor therapy. A study of 16 biopsies. Am J Dermatopathol. 2010 Aug; 32(6):568-73. View Abstract

  152. Interactive medical case. A rash hypothesis. N Engl J Med. 2010 Jun 17; 362(24):e69. View Abstract

  153. The role of octopamine in locusts and other arthropods. J Insect Physiol. 2010 Aug; 56(8):854-67. View Abstract

  154. The cloning, phylogenetic relationship and distribution pattern of two new putative GPCR-type octopamine receptors in the desert locust (Schistocerca gregaria). J Insect Physiol. 2010 Aug; 56(8):868-75. View Abstract

  155. Mitochondrial DNA deletions serve as biomarkers of aging in the skin, but are typically absent in nonmelanoma skin cancers. J Invest Dermatol. 2006 Feb; 126(2):336-44. View Abstract

  156. High-throughput mitochondrial genome screening method for nonmelanoma skin cancer using multiplexed temperature gradient capillary electrophoresis. Clin Chem. 2005 Feb; 51(2):305-11. View Abstract
BESbswy